NEW YORK (GenomeWeb News) – Accelrys today reported that revenue for its second fiscal quarter decreased by 1 percent to $20 million from $20.1 million in the prior-year period.
For the three months ended Sept. 30, the company's net income climbed 50 percent to $1.8 million, or $0.07 per diluted share, from $1.2 million, or $0.04 per diluted share, for the same quarter of the previous year.
Second-quarter product development costs decreased 5 percent to $3.6 million from $3.8 million year-over-year.
Sales and marketing costs also decreased by 5 percent, to $7.8 million from $8.2 million, while general and administrative costs rose 3 percent to $3.4 million from $3.3 million in the comparable prior-year period.
As of Sept. 30, Accelrys had $80 million in cash, cash equivalents, and marketable securities.